XML 23 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Millions
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Retained Earnings
Beginning balance (in shares) at Dec. 31, 2020   394,300,000      
Beginning balance at Dec. 31, 2020 $ 5,375.2 $ 3.9 $ 4,204.7 $ (0.9) $ 1,167.5
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Restricted stock grants surrendered 292.6       292.6
Other comprehensive (loss) income (4.9)     (4.9)  
Exercise of stock options (in shares)   200,000      
Exercise of stock options 6.3   6.3    
Restricted stock issued (in shares)   900,000      
Restricted stock grants surrendered (in shares)   (600,000)      
Restricted stock grants surrendered (33.3)   (33.3)    
Stock-based compensation expense 62.6   62.6    
Employee stock purchase plan (in shares)   200,000      
Employee stock purchase plan 13.0   13.0    
Ending balance (in shares) at Dec. 31, 2021   395,000,000.0      
Ending balance at Dec. 31, 2021 5,711.5 $ 3.9 4,253.3 (5.8) 1,460.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Restricted stock grants surrendered 369.5       369.5
Other comprehensive (loss) income (23.3)     (23.3)  
Restricted stock issued (in shares)   1,500,000      
Restricted stock grants surrendered (in shares)   (700,000)      
Restricted stock grants surrendered (23.1)   (23.1)    
Stock-based compensation expense $ 74.6   74.6    
Employee stock purchase plan (in shares) 223,596 200,000      
Employee stock purchase plan $ 15.0   15.0    
Stock issued for equity offerings, net of transaction costs (in shares)   10,700,000      
Stock issued for equity offerings, net of transaction costs 745.7 $ 0.1 745.6    
Ending balance (in shares) at Dec. 31, 2022   406,700,000      
Ending balance at Dec. 31, 2022 6,870.0 $ 4.1 5,065.4 (29.1) 1,829.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Restricted stock grants surrendered 374.7       374.7
Other comprehensive (loss) income 11.5     11.5  
Exercise of stock options (in shares)   400,000      
Exercise of stock options 7.5   7.5    
Restricted stock issued (in shares)   1,400,000      
Restricted stock grants surrendered (in shares)   (700,000)      
Restricted stock grants surrendered (23.2)   (23.2)    
Stock-based compensation expense 83.6   83.6    
Management stock purchase plan (in shares)   100,000      
Management stock purchase plan $ (3.2)   (3.2)    
Employee stock purchase plan (in shares) 227,939 200,000      
Employee stock purchase plan $ 17.7   17.7    
Ending balance (in shares) at Dec. 31, 2023   408,100,000      
Ending balance at Dec. 31, 2023 $ 7,338.6 $ 4.1 $ 5,147.8 $ (17.6) $ 2,204.3